Miruvor
Sign up
The short answer

What studies of Lisdexamfetamine (Vyvanse, Elvanse) found

6papers on Lisdexamfetamine (Vyvanse, Elvanse)
1 (few people)person in 1 study testing Lisdexamfetamine (Vyvanse, Elvanse) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 4 of 5 findings are C.

5 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Lisdexamfetamine (Vyvanse, Elvanse) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 6 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Lisdexamfetamine (Vyvanse, Elvanse) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue1 study · 1 (few people) person took Lisdexamfetamine (Vyvanse, Elvanse) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 18 months · 30 mg upon waking; doubled to 60 mg; soon to 70 mg; 30 mg at 8 AM and 30 mg at 12 AM, upon waking; 30 mg at 8 AM and 30 mg at 12 AM (few people)

Fatigue improved.

The evidence is very uncertain about the effect of lisdexamfetamine (Vyvanse, Elvanse) on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    30 mg upon waking; doubled to 60 mg; soon to 70 mg; 30 mg at 8 AM and 30 mg at 12 AM, upon waking; 30 mg at 8 AM and 30 mg at 12 AM
    Outcome
    Fatigue with LDX
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Sleep1 study · 1 (few people) person took Lisdexamfetamine (Vyvanse, Elvanse) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 18 months · 30 mg upon waking; doubled to 60 mg; soon to 70 mg; 30 mg at 8 AM and 30 mg at 12 AM, upon waking; 30 mg at 8 AM and 30 mg at 12 AM (few people)

Sleep improved.

The evidence is very uncertain about the effect of lisdexamfetamine (Vyvanse, Elvanse) on sleep in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    30 mg upon waking; doubled to 60 mg; soon to 70 mg; 30 mg at 8 AM and 30 mg at 12 AM, upon waking; 30 mg at 8 AM and 30 mg at 12 AM
    Outcome
    Insomnia with trazodone
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 1 (few people) person took Lisdexamfetamine (Vyvanse, Elvanse) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all).

Studies with no comparison group1 in the study · 18 months · 30 mg upon waking; doubled to 60 mg; soon to 70 mg; 30 mg at 8 AM and 30 mg at 12 AM, upon waking; 30 mg at 8 AM and 30 mg at 12 AM (few people)

No clear change in cognition (brain fog).

The evidence is very uncertain about the effect of lisdexamfetamine (Vyvanse, Elvanse) on cognition (brain fog) in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
See the 1 study
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    30 mg upon waking; doubled to 60 mg; soon to 70 mg; 30 mg at 8 AM and 30 mg at 12 AM, upon waking; 30 mg at 8 AM and 30 mg at 12 AM
    Outcome
    Effectiveness of LDX 60 mg versus 70 mg
    Effect
    no clear difference
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 1 (few people) person took Lisdexamfetamine (Vyvanse, Elvanse) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 18 months · 30 mg upon waking; doubled to 60 mg; soon to 70 mg; 30 mg at 8 AM and 30 mg at 12 AM, upon waking; 30 mg at 8 AM and 30 mg at 12 AM (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of lisdexamfetamine (Vyvanse, Elvanse) on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    30 mg upon waking; doubled to 60 mg; soon to 70 mg; 30 mg at 8 AM and 30 mg at 12 AM, upon waking; 30 mg at 8 AM and 30 mg at 12 AM
    Outcome
    Medication coverage across all hours
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took Lisdexamfetamine (Vyvanse, Elvanse) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 18 months · 30 mg upon waking; doubled to 60 mg; soon to 70 mg; 30 mg at 8 AM and 30 mg at 12 AM, upon waking; 30 mg at 8 AM and 30 mg at 12 AM (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of lisdexamfetamine (Vyvanse, Elvanse) on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    30 mg upon waking; doubled to 60 mg; soon to 70 mg; 30 mg at 8 AM and 30 mg at 12 AM, upon waking; 30 mg at 8 AM and 30 mg at 12 AM
    Outcome
    Overall treatment response
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Stopping because of side effects1 study
Side effects studies reported3 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Trouble sleeping2 studies
Anxiety or irritability1 study
Headache1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    30 to 70 mg at the start

  2. 2Raise

    Raised step by step in 2 of 3 studies

  3. 3Top dose

    Most often 70 mg (2 of 3 studies)

Doses across 3 studies

30 to 70 mg.

Each study’s dose, as printed

All papers

  1. Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: a double blind, placebo-controlled study.2013 · placebo trial · 26 randomised
    Summary

    Twenty-six adults with chronic fatigue syndrome and clinically significant executive functioning deficits were randomly assigned to a flexible morning dose of lisdexamfetamine dimesylate (30, 50, 70 mg/day) or placebo for a 6-week trial at the Rochester Center for Behavioral Medicine. Fifteen participants were assigned to LDX and 11 to placebo. The primary measure was the Behavior Rating Inventory of Executive Function—Adult Global Executive Composite (BRIEF—A GEC); secondary measures included the Fatigue Severity Scale (FSS), McGill Pain Questionnaire, Fibromyalgia Impact Questionnaire (FIQ), Clinical Global Impression—Severity (CGI-S), ADHD Rating Scale (ADHDRS), and Hamilton Anxiety Scale (HAM-A). On the GEC, the LDX group showed a mean change of 21.38 (S.D. 15.85) versus 3.36 (S.D. 7.26) with placebo (p=0.005). The LDX group also showed more change on the FSS (20.92 vs 5.00; p=0.008), McGill (10.38 vs 2.45; p=0.046), CGI-S (1.92 vs 0.64; p=0.022), and ADHDRS (18.17 vs 8.73; p=0.038). There were no statistically significant differences on the FIQ (20.90 vs 8.83; p=0.219), HAM-A (11.31 vs 6.18; p=0.183), or endpoint pulse (77.77 vs 75.27; p=0.644). Adverse events included headache (LDX 15.38%/placebo 7.7%), dry mouth (7.7%/0%), and insomnia (7.7%/0%); two LDX participants discontinued due to adverse events (insomnia at visit 3, anxiety at visit 5), and placebo discontinuations were 0.

  2. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report.2023 · case report · 1 in the study
    Summary

    A single case study reports a 61-year-old man with Post-COVID-19 Syndrome (PCS) or Long COVID, treated on an outpatient basis and self-referred. He received Immediate-Release Methylphenidate (IR-MPH) started at 5 mg/day and increased to 10 mg TID, then Lisdexamfetamine (LDX) 30 mg upon waking, doubled to 60 mg and soon to 70 mg, with Bupropion XL up to 300 mg/day. The PCS treatment lasted 18 months. ADHD-like symptoms were measured with the Adult ADHD Self-Report Screening Scale (ASRS; total score 0 to 72). Baseline ASRS was 40. IR-MPH initially reduced symptoms to 28 points (30% reduction from baseline); ASRS returned to baseline (40 points) after IR-MPH interruption. Fatigue was fully treated with LDX, but ADHD-like symptoms remained unchanged after some weeks; there was no difference in effectiveness between 60 or 70 mg of LDX. A split LDX plus IR-MPH scheme used for 1 month reduced ASRS to 25 points (37,5% reduction from baseline). After 5 weeks, bupropion add-on reduced ASRS to 17 from the baseline 40 points, a 57,5% reduction and remission of symptoms since the cutoff is 24 points. The final drug combination remained well tolerated. The only adverse effect of the final drug combination was a weight loss of 5 kg that did not disturb the patient; increasing IR-MPH doses was not well tolerated due to insomnia, and the patient did not experience side effects with LDX. Authors state limitations are inherent to a case study and that replication in more patients with PCAS is needed.

  3. Proceedings #19. Maintenance tDCS: A Case of Full and Durable Recovery from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)2017 · case report · 1 in the study
    Summary

    This conference proceeding reports a case report of one 61-year-old man with treatment-resistant progressive ME/CFS who was referred for neuromodulation. There was no comparison group. He was trained in the office and then self-administered tDCS at home daily, with anode on the left dorsolateral prefrontal cortex, cathode on the right dorsolateral prefrontal cortex, 2 mA/min, 20 minutes, 40 mA total dose, using 1.5” diameter electrode pads. After four weeks, sessions were increased to twice daily (6 AM and 12 Noon). Modafinil 200 mg provided partial relief of fatigue; later the dose was lowered to 100 mg due to insomnia, and modafinil was stopped but resumed at 100 mg daily after he felt less well. The paper reports one year of maintenance tDCS and follow-up neurophysiological studies 14 months after initial presentation. It reports significant benefit early in the day during the first month of daily tDCS, consistent benefit after twice-daily sessions, and full clinical recovery over the next few months, with improved exercise tolerance and a return to physical exercise several times each week. Before treatment, omission errors were 14.29%; after treatment, behavioral measures were within the normal rage and there were no omission errors. The patient reported sustained relief. The authors state that data were not shown for frontocentral infra-slow frequency drift.

  4. Chronic fatigue syndrome: 3 cases and a discussion of the natural history of attention-deficit/hyperactivity disorder.2013 · case report · 3 in the study
    Summary

    This case series describes 3 patients with chronic fatigue syndrome who were referred for psychiatric consultation and evaluated at the Rochester Center for Behavioral Medicine outside of Detroit, MI. All 3 began long-acting psychostimulant medication. Irene (Patient 1) received osmotic-controlled release oral delivery system (OROS®) methyl phenidate tablets (Concerta®), titrated to 54 mg/morning. Katherine (Patient 2) received amphetamine/dextroamphetamine extended-release tablets (Adderall XR®) at 30 mg/morning. Alice (Patient 3) received lisdexamfetamine (Vyvanse®), starting at 30 mg/morning and titrated from 30 mg/morning to 70 mg/morning over a 6-week period. Katherine and Alice continued antidepressant medications. The Fatigue Severity Scale and Epworth Sleepiness Scale were repeated 4 weeks after the beginning of stimulant treatment. After treatment with psychostimulants, the 3 patients reported improved symptoms of fatigue and pain, and cognitive and core ADHD symptoms; with psychostimulant treatment, all 3 noted marked improvement of fatigue and cognitive symptoms. Fatigue Severity Scale scores were 60 to 30 for Irene, 56 to 34 for Katherine, and 58 to 24 for Alice. Epworth Sleepiness Scale scores were 7 to 7 for Irene, 10 to 6 for Katherine, and 11 to 9 for Alice. There was no comparison group and no randomisation. Harms were not reported. The authors state this is a preliminary finding and further research is needed before recommendations.

  5. Update of the Potential Treatments for Psychiatric and Neuropsychiatric Symptoms in the Context of the Post-COVID-19 Condition: Still a Lot of Suffering and Many More Things to Learn2022 · systematic review
    Summary

    This review from Geneva searched two literature databases up to 1 January 2022 for ways to manage and treat psychiatric and neuropsychiatric symptoms of the post-COVID-19 condition, such as depression, anxiety, post-traumatic stress, fatigue, sleep and memory problems. It included 43 articles, most of them reviews, letters and consensus statements rather than treatment studies. Only a few included studies tested a treatment in people with post-COVID symptoms: a clinical trial of 60 people with post-COVID depression in which 92% had a reduction of HDRS >50% with antidepressants after one month; a case series of three people given tofisopam, described as easing anxiety and depression without sedation or muscle relaxation; a study of 30 patients in which a psychological programme (breathing exercises, autogenic training, activity scheduling and social support) was followed by a significant improvement on a mental health inventory; and a letter reporting good results with lisdexamfetamine in a small sample. Most other options discussed (apheresis, vagus nerve stimulation, monoclonal antibodies, flavonoids such as luteolin and quercetin, oxytocin, L-carnitine and adapted CBT for fatigue) had no trial results at the time. The authors call SSRIs the best choice for post-COVID depression and anxiety, advise caution with lisdexamfetamine because of addiction risk, and note they found just one study of antidepressants for post-COVID depression.

  6. A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.2016 · systematic review
    Summary

    This systematic review examined drug therapies for chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME). Ovid MEDLINE, EMBASE, and PubMed were searched from the beginning of their archives to March 2016. The review included 26 randomized, placebo-controlled trials that met its criteria; these trials tested 20 drug therapies. The review reports effectiveness by categories from not effective to highly effective and says no universal pharmaceutical treatment can be recommended. Hydrocortisone findings were conflicting: across studies it was reported as mildly effective, slightly effective, not effective, and moderately effective; in one study the well-being improvement was not significant, and Blockmans et al found no clinical improvement. Rituximab was reported to produce a significant and lasting improvement, but the review states it is premature to conclude a lasting improvement in primary assessed domains; primary end points were evaluated for 3 months and secondary end points up to 12 months. For intravenous immunoglobulin, Rowe reported headache, fatigue, and difficulty concentrating significantly worse in the intervention group after the first infusion, with no differences after the third and final infusion. The review states no pharmaceutical therapy resulted in severe adverse events. It notes nefazodone was discontinued in 2004 after patients developed hepatic and visual disorders. Forsyth et al and Young each had N = 26; Young lacked male participants in the intervention cohort. The authors state that no clear recommended pharmaceutical therapy for CFS/ME exists and call for standardized diagnostic criteria and outcome measurements.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime